For the Inventor, By the Inventor

Enter assignee name

Bothell, WA, United States of America

Seagen Inc.

USPTO Granted Patents = 66

% Expired Patents = 4.5

CIPO Patents = 4

EPO Patents = 21

Trademarks = 21

Forward Citations = 49

Loading Chart...

Loading Chart...

97 inventors (with patents filed for the assignee):

Lori Westendorf (9 out of 11 patents)

Shyra Gardai (7 out of 8 patents)

Django Sussman (7 out of 20 patents)

4. Patrick J Burke (7 out of 26 patents)

5. Dana Kennedy (6 out of 12 patents)

6. Peter Senter (6 out of 47 patents)

7. Eric Sievers (5 out of 16 patents)

8. Che-Leung Law (5 out of 20 patents)

9. Robert Lyon (5 out of 8 patents)

10. Scott Peterson (4 out of 6 patents)

11. Scott C Jeffrey (4 out of 30 patents)

12. Karen Jane Meyrick Morrison (4 out of 68 patents)

13. Vivian Trang (4 out of 4 patents)

14. Matthew R Levengood (4 out of 4 patents)

15. Travis Biechele (4 out of 4 patents)

Core Competencies:

Antibody Drug Conjugates

CD30

HER2

PI3K-AKT

Auristatin

BCMA

CD47

Fucosylation

Tumor Treatment

Drug Linkers

Combination Therapy

Glycan-Interacting

66 patents: Sort by Forward Citations

1. 12590968 - Detection and treatment of CD30+ cancers (2026-03-31),

2. 12496353 - SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE PI3K-AKT MTOR PATHWAY (2025-12-16),

3. 12421312 - Anti-PD-L1 antibodies and antibody-drug conjugates (2025-09-23),

4. 12268751 - Anti-αVβ6 antibodies and antibody-drug conjugates (2025-04-08),

5. 12257340 - Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof (2025-03-25),

6. 12257281 - Hydrophilic antibody-drug conjugates (2025-03-25),

7. 12194321 - Camptothecin conjugates (2025-01-14),

8. 12071480 - CD47 antibodies and uses thereof for treating cancer (2024-08-27),

9. 12048698 - Treatment of HER2 positive cancers (2024-07-30),

10. 12036286 - Selective drug release from internalized conjugates of biologically active compounds (2024-07-16),

11. 11944689 - Drug conjugates with self-stabilizing linkers having improved physiochemical properties (2024-04-02),

12. 11938194 - Cysteine mutated antibodies for conjugation (2024-03-26),

13. 11931414 - Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates (2024-03-19),

14. 11891644 - T cells with reduced surface fucosylation and methods of making and using the same (2024-02-06),

15. 11857565 - Hydrophobic Auristatin F compounds and conjugates thereof (2024-01-02),

Company Overview

Seagen Inc., headquartered in Bothell, Washington, specializes in the development of innovative therapies using antibody-drug conjugates (ADCs). The company focuses on targeting specific cancer cells through advanced technologies, including CD30, HER2, and BCMA, to enhance treatment efficacy while minimizing side effects. Seagen's research also delves into critical pathways such as PI3K-AKT and mechanisms like fucosylation, positioning it as a leader in the biopharmaceutical landscape dedicated to improving patient outcomes in oncology.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

66 Patents

#8 in Bothell, WA

#112 in Washington

#5,530 in US

#11,167 in the World

Bothell, WA, United States of America

Seagen Inc.

Forward Citations = 49

97 inventors:

Lori Westendorf (9 out of 11 patents)

Shyra Gardai (7 out of 8 patents)

Django Sussman (7 out of 20 patents)

4. Patrick J Burke (7 out of 26 patents)

5. Dana Kennedy (6 out of 12 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Seagen Inc.. Retrieved from https://idiyas.com/company/seagen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…